Partner Content Partner Content Less than 4 Weeks until Immuno-Therapy Experts Gather at the... Less than 4 Weeks until Immuno-Oncology Conference
Partner Content Partner Content Invitation from Chair of this year’s Immuno-Oncology Confere... Invitation from Chair of Immuno-Oncology Conference
News Avelumab filed, Pfizer and Merck prepare to join immunothera... Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market
News Boehringer and Sarah Cannon team for immune-oncology venture Partnership will seek to develop two immune checkpoint inhibitor candidates.